Skip to main content

Chronic Kidney Disease, Diabetes Mellitus, Hypertension and Medication Possession Ratio for ACEI/ARB Therapy

CBE ID
0550
1.4 Project
Renal Consensus Standards Endorsement Maintenance
Endorsement Status
Endorsement Removed
1.1 New or Maintenance
Maintenance
Previous Endorsement Cycle
Full Year 2011
Is Under Review
No
1.3 Measure Description

Medication Possession Ratio (MPR) for ACEI/ARB therapy for individuals with Chronic Kidney Disease (CKD) and/or diabetes mellitus and hypertension.

    • 1.14 Numerator

      The sum of the days supply that fall within the measurement window for an ACEI/ARB fill for each patient in the denominator.

      Time window: Anytime during the measurement period (12 months)

      MPR Numerator:
      1. New users: For patients with no prescriptions in the 180 days prior to the measurement period, sum of:

      Days’ supply of all medications from the first prescription until the end of the measurement period.

      **Remove the days’ supply that extend past the end of the measurement period.

      2. Continuous users: For patients with 1 or more prescriptions in the 180 days prior to the measurement period, sum of:

      Days’ supply of all medications in the measurement period

      **Remove the days supply that extends past the end of the measurement period and add days supply from the previous period that apply to the current period.

    • 1.15 Denominator

      Beneficiaries with CKD stages 1-4 and/or diabetes mellitus and hypertension (HTN) identified during the measurement period with at least one Part D claim for an ACEI/ARB.

      Time window: Anytime during the measurement period (12 consecutive months)

      MPR Denominator:
      1. New users: Number of days from the first prescription to the end of measurement period.
      2. Continuous users: Number of days from the beginning to the end of the measurement period

    • Exclusions

      Patients who died during the measurement period.
      Patients who are actively enrolled in multiple plans concurrently as of the end of the measurement period.
      Patients who have had a kidney transplant during the measurement period.
      Patients who have ESRD.
      Patients with a diagnosis of polycystic ovaries who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period.
      Patients with a diagnosis of gestational diabetes or steroid-induced diabetes who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period.

    • Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Renal Consensus Standards Endorsement Maintenance 2011
      Initial Endorsement
      Last Updated
      Removal Date
    • Steward
      Centers for Medicare & Medicaid Services
      Steward Organization POC Email
      [email protected]